Previous 10 | Next 10 |
home / stock / blue / blue articles
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebir...
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the ...
NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims a...
NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the ...
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and ...
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims a...
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the ...
NEW YORK, May 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securitie...
NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the ...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...